Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 Dec 2020
Historique:
received: 22 10 2020
revised: 23 11 2020
accepted: 04 12 2020
entrez: 9 12 2020
pubmed: 10 12 2020
medline: 5 3 2021
Statut: epublish

Résumé

Activation of P2X7 signaling, due to high glucose levels, leads to blood retinal barrier (BRB) breakdown, which is a hallmark of diabetic retinopathy (DR). Furthermore, several studies report that high glucose (HG) conditions and the related activation of the P2X7 receptor (P2X7R) lead to the over-expression of pro-inflammatory markers. In order to identify novel P2X7R antagonists, we carried out virtual screening on a focused compound dataset, including indole derivatives and natural compounds such as caffeic acid phenethyl ester derivatives, flavonoids, and diterpenoids. Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) rescoring and structural fingerprint clustering of docking poses from virtual screening highlighted that the diterpenoid dihydrotanshinone (DHTS) clustered with the well-known P2X7R antagonist JNJ47965567. A human-based in vitro BRB model made of retinal pericytes, astrocytes, and endothelial cells was used to assess the potential protective effect of DHTS against HG and 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate (BzATP), a P2X7R agonist, insult. We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels. Furthermore, HG levels and P2X7R agonist treatment led to increased expression of pro-inflammatory mediators (TLR-4, IL-1β, IL-6, TNF-α, and IL-8) and other molecular markers (P2X7R, VEGF-A, and ICAM-1), along with enhanced production of reactive oxygen species. Treatment with DHTS preserved the BRB integrity from HG/BzATP damage. The protective effects of DHTS were also compared to the validated P2X7R antagonist, JNJ47965567. In conclusion, we provided new findings pointing out the therapeutic potential of DHTS, which is an inhibitor of P2X7R, in terms of preventing and/or counteracting the BRB dysfunctions elicited by HG conditions.

Identifiants

pubmed: 33291318
pii: ijms21239305
doi: 10.3390/ijms21239305
pmc: PMC7730037
pii:
doi:

Substances chimiques

Connexin 43 0
Cytokines 0
Furans 0
Phenanthrenes 0
Purinergic P2X Receptor Agonists 0
Purinergic P2X Receptor Antagonists 0
Quinones 0
Reactive Oxygen Species 0
Receptors, Purinergic P2X7 0
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 4P5DXU1F8Q
dihydrotanshinone I 562G9360V6
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Education, University and Research (MIUR)
ID : PRIN 2015JXE7E8
Organisme : Italian Ministry of Economic Development (MISE) PON-Innovative PhD Program XXXIII
ID : E37H18000340006
Organisme : PIACERI 2020/2022
ID : Linea Intervento 2, University of Catania

Références

Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3758-63
pubmed: 20130277
J Ophthalmic Vis Res. 2014 Jul-Sep;9(3):362-73
pubmed: 25667739
Am J Physiol Cell Physiol. 2011 Nov;301(5):C1213-23
pubmed: 21832250
Drugs Context. 2018 Aug 13;7:212532
pubmed: 30181760
Front Pharmacol. 2018 Feb 01;9:39
pubmed: 29449813
J Ophthalmol. 2017;2017:9402198
pubmed: 28680705
Glia. 2014 Sep;62(9):1486-501
pubmed: 24839011
Pathophysiology. 2017 Dec;24(4):229-241
pubmed: 28732591
BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Free Radic Biol Med. 2010 May 1;48(9):1121-32
pubmed: 20083193
Biochem Pharmacol. 2017 Aug 15;138:130-139
pubmed: 28479300
Expert Opin Investig Drugs. 2011 Jul;20(7):897-915
pubmed: 21510825
Br J Pharmacol. 2013 Oct;170(3):624-40
pubmed: 23889535
World J Diabetes. 2014 Apr 15;5(2):141-5
pubmed: 24748927
Int J Mol Sci. 2020 Feb 27;21(5):
pubmed: 32121029
Sci Rep. 2016 Jul 06;6:29393
pubmed: 27381080
Exp Cell Res. 2017 Sep 1;358(1):39-44
pubmed: 28372972
J Ocul Pharmacol Ther. 2020 Jan/Feb;36(1):30-41
pubmed: 31140899
Biochem Pharmacol. 2019 Oct;168:249-258
pubmed: 31302133
Biochem Pharmacol. 2020 May;175:113908
pubmed: 32171729
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5594-5603
pubmed: 29084332
Exp Diabetes Res. 2010;2010:247861
pubmed: 21052489
Vision (Basel). 2018 Sep;2(3):
pubmed: 30288454
Mol Vis. 2009 Jul 25;15:1418-28
pubmed: 19641635
PLoS One. 2015 May 04;10(5):e0125111
pubmed: 25938443
Biochem Pharmacol. 2020 Oct;180:114199
pubmed: 32798466
Pflugers Arch. 2017 Jan;469(1):55-67
pubmed: 27624415
Front Pharmacol. 2017 Mar 16;8:123
pubmed: 28360855
Biochem Pharmacol. 2017 Oct 15;142:145-154
pubmed: 28651842
J Clin Invest. 1996 Jun 15;97(12):2883-90
pubmed: 8675702
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2408-13
pubmed: 11527957
Circ Res. 2002 Mar 22;90(5):570-7
pubmed: 11909821
Methods Mol Biol. 2011;686:133-48
pubmed: 21082369
Sci Rep. 2019 Dec 13;9(1):19059
pubmed: 31836806
Int J Retina Vitreous. 2019 Oct 1;5:29
pubmed: 31583119
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836-41
pubmed: 10485912
Cell. 2019 Oct 17;179(3):659-670.e13
pubmed: 31587896
J Physiol. 2003 Sep 15;551(Pt 3):787-99
pubmed: 12876212
Diabet Med. 2002 May;19(5):371-6
pubmed: 12027924
Clin Exp Ophthalmol. 2016 May;44(4):260-77
pubmed: 26716602
Int J Cancer. 2019 Aug 15;145(4):1068-1082
pubmed: 30761524
Arch Ophthalmol. 2000 Oct;118(10):1364-9
pubmed: 11030818
Front Pharmacol. 2019 Jun 21;10:693
pubmed: 31293421
Mol Biol Cell. 2006 Apr;17(4):1922-32
pubmed: 16436508
Antioxid Redox Signal. 2010 Jun 15;12(12):1431-70
pubmed: 19803744
Lancet. 1994 Apr 2;343(8901):831-6
pubmed: 7908081
Invest Ophthalmol Vis Sci. 2013 Oct 03;54(10):6518-25
pubmed: 24008412
Curr Eye Res. 2014 Feb;39(2):105-19
pubmed: 24144321
Epilepsia. 2017 Jul;58 Suppl 3:27-38
pubmed: 28675563
Antioxidants (Basel). 2019 Aug 06;8(8):
pubmed: 31390749
J Biol Chem. 2004 Oct 22;279(43):44785-94
pubmed: 15292177
J Ophthalmol. 2015;2015:605946
pubmed: 25821590
Acta Diabetol. 2019 Sep;56(9):1031-1036
pubmed: 30982154
Biochem Pharmacol. 2020 Aug;178:114110
pubmed: 32569630
J Cell Physiol. 2017 May;232(5):1079-1085
pubmed: 27486932
J Cell Sci. 2015 Dec 15;128(24):4615-28
pubmed: 26542019
Future Med Chem. 2019 Jul;11(13):1523-1536
pubmed: 31469335
Pharmacol Res. 2019 Apr;142:102-114
pubmed: 30794925
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179-83
pubmed: 17896294
Med Sci Monit. 2020 Feb 29;26:e920738
pubmed: 32112706
Saudi J Ophthalmol. 2018 Oct-Dec;32(4):318-323
pubmed: 30581303
J Med Chem. 2004 Jan 15;47(2):337-44
pubmed: 14711306
Micromachines (Basel). 2020 Jun 15;11(6):
pubmed: 32549277
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Sci Rep. 2019 Sep 19;9(1):13587
pubmed: 31537874
Diabetes. 2007 Jan;56(1):224-30
pubmed: 17192486
J Mol Histol. 2008 Apr;39(2):243-9
pubmed: 18165914
Eye (Lond). 2018 Jul;32(7):1157-1163
pubmed: 29520046
J Biochem Mol Biol. 2006 Sep 30;39(5):469-78
pubmed: 17002866
Nat Commun. 2016 Feb 15;7:10555
pubmed: 26877061
Sci Rep. 2018 Sep 20;8(1):14117
pubmed: 30237412
Br J Pharmacol. 2000 Jul;130(5):963-74
pubmed: 10882379
Exp Eye Res. 2012 Mar;96(1):181-90
pubmed: 22200486
Int J Ophthalmol. 2019 Feb 18;12(2):302-311
pubmed: 30809489
Oxid Med Cell Longev. 2017;2017:3940241
pubmed: 29410732
Purinergic Signal. 2018 Dec;14(4):471-484
pubmed: 30415294
Exp Eye Res. 2013 Oct;115:162-71
pubmed: 23891860
Vision Res. 2017 Oct;139:123-137
pubmed: 28619516
J Pharmacol Sci. 2018 Dec;138(4):219-232
pubmed: 30503676
Am J Physiol Cell Physiol. 2005 Mar;288(3):C568-76
pubmed: 15496477
J Diabetes Res. 2014;2014:790902
pubmed: 25610879
JCI Insight. 2019 Mar 19;5:
pubmed: 30888334
J Diabetes Res. 2019 Aug 14;2019:8562408
pubmed: 31511825
Sci Rep. 2015 Nov 10;5:16478
pubmed: 26553968
Front Pharmacol. 2018 Feb 01;9:30
pubmed: 29449810
Exp Eye Res. 2014 Oct;127:270-9
pubmed: 25151301

Auteurs

Claudia Giuseppina Fresta (CG)

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.

Giuseppe Caruso (G)

Department of Drug Sciences, University of Catania, 95125 Catania, Italy.
Oasi Research Institute-IRCCS, 94018 Troina, Italy.

Annamaria Fidilio (A)

Department of Drug Sciences, University of Catania, 95125 Catania, Italy.

Chiara Bianca Maria Platania (CBM)

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.

Nicolò Musso (N)

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.

Filippo Caraci (F)

Department of Drug Sciences, University of Catania, 95125 Catania, Italy.
Oasi Research Institute-IRCCS, 94018 Troina, Italy.

Filippo Drago (F)

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Center for Research in Ocular Pharmacology-CERFO, University of Catania, 95125 Catania, Italy.

Claudio Bucolo (C)

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Center for Research in Ocular Pharmacology-CERFO, University of Catania, 95125 Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH